Literature DB >> 34857080

In Reply.

Ulrike Höller, Michael Oertel.   

Abstract

Entities:  

Year:  2021        PMID： 34857080      PMCID： PMC8704826          DOI： 10.3238/arztebl.m2021.0280

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

Authors:  Charles N Catton; Himu Lukka; Chu-Shu Gu; Jarad M Martin; Stéphane Supiot; Peter W M Chung; Glenn S Bauman; Jean-Paul Bahary; Shahida Ahmed; Patrick Cheung; Keen Hun Tai; Jackson S Wu; Matthew B Parliament; Theodoros Tsakiridis; Tom B Corbett; Colin Tang; Ian S Dayes; Padraig Warde; Tim K Craig; Jim A Julian; Mark N Levine
Journal:  J Clin Oncol       Date:  2017-03-15       Impact factor: 44.544

2.  Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.

Authors:  Giorgio Arcangeli; Biancamaria Saracino; Stefano Arcangeli; Sara Gomellini; Maria Grazia Petrongari; Giuseppe Sanguineti; Lidia Strigari
Journal:  J Clin Oncol       Date:  2017-03-29       Impact factor: 44.544

3.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

Review 4.  Late Sequelae of Radiotherapy—The Effect of Technical and Conceptual Innovations in Radiation Oncology.

Authors:  Ulrike Hoeller; Kerstin Borgmann; Michael Oertel; Uwe Haverkamp; Volker Budach; Hans Theodor Eich
Journal:  Dtsch Arztebl Int       Date:  2021-03-26       Impact factor: 5.594
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.